Over the past decade, neuroscience has undergone a revolution. From the rise of precision medicine to the resurgence of psychedelics and the advent of RNA technologies, we’re witnessing unprecedented advancements that are reshaping the future of human health. For Canadian innovators working in these fields, the stakes have never been more promising. Canada has always been a hub of innovation in biotechnology and healthcare, but today, the country stands at the forefront of a revolution that could reshape the future of medicine.
The convergence of these cutting-edge domains offers a unique opportunity for Canada to assert itself as a global leader in neurotechnology. Through strategic financing and partnerships, the Canadian biotech sector is perfectly positioned to lead this charge on a global scale.
The Evolution of Neuroscience: A Decade of Transformation
Precision Medicine: Towards Tailored Therapies
Over the last decade, precision medicine has moved from being a concept treatment approach to an actionable one. The understanding that no two patients are alike has driven the shift away from traditional one-size-fits-all medical treatment approaches. By integrating genetic, environmental, and lifestyle factors with molecular and clinical data, precision medicine allows for personalized treatment strategies.
In Canada, precision medicine has seen significant advancements, particularly in oncology and cardiovascular diseases. However, the most exciting developments are happening in neuroscience. Neurological disorders like Alzheimer’s, Parkinson’s, and multiple sclerosis have long eluded effective treatments. However, through precision medicine, we’re now able to target the root causes of these diseases at a molecular level and optimize treatment through the use of biomarkers to identify disease subtypes and predict individual responses to therapies (Rabinovici et al., 2019). This highlights the transformative potential of precision medicine in neuroscience in revolutionizing the future of healthcare.
Psychedelics: A Renaissance in Mental Health Treatment
Contrastingly, over the last decade, modern neuroscience has undergone a psychedelic renaissance, from once being relegated to the fringes of scientific research, to now being intensively studied for its potential in treating a range of mental health conditions, including depression, PTSD, and anxiety.
Canada has been at the forefront of this resurgence. In 2020, Health Canada granted an exemption allowing psilocybin-assisted therapy for patients with terminal illnesses, marking a significant step toward broader acceptance of psychedelic therapies (Controlled Drugs and Substances Act(CDSA), Subsection 56(1)). Since then, several clinical trials have been launched across the country, exploring the efficacy of these substances in treating conditions that are resistant to traditional therapies. Continuing the charge in this domain, Canada has the potential to not only transform mental health treatment but also challenge the long-held stigmas about psychedelics, by developing psychedelic-inspired medical therapies, conducting large-scale clinical trials and investigating its use cases.
RNA Technologies: The Future of Gene Editing and Therapy
RNA technologies have emerged as a powerful tool in the treatment of diseases at the genetic level, with the development of mRNA vaccines during the COVID-19 pandemic showcasing the potential of this technology. However, its applications extend far beyond infectious diseases.
Within the neuroscientific domain, they are emerging as transformative tools, offering novel therapeutic and diagnostic avenues for neurodegenerative diseases. RNA-based therapies are being explored for their ability to silence or modify the expression of specific genes associated with neurological disorders. For instance, Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) have shown great promise in targeting specific RNA transcripts, enabling precise modulation of gene expression in neurodegenerative conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and Huntington’s disease (Rinaldi & Wood, 2018). This exemplifies the potential for RNA technologies to not only treat but potentially cure conditions that have long been considered untreatable, revolutionizing the treatment of neurological disorders.
The Current Landscape: Challenges and Opportunities
As we stand at the intersection of these three domains, the current landscape is one of both promise and challenge.Canadian innovators are well-positioned to capitalize on the advances in precision medicine, psychedelics, and RNA technologies, but several hurdles remain.
One of the primary challenges facing these industries is the regulatory environment. In Canada, Health Canada’s approval process for new therapies, particularly those involving psychedelics, can be lengthy and complex. Ethical considerations also play a significant role, especially in the context of gene editing and psychedelics. The potential to modify the human genome and the use of psychedelics in therapy raises questions about long-term impacts and the moral implications of such technologies.
Secondly, developing new therapies, particularly in neuroscience, is a financially intensive endeavor that requires substantial investment. While the Canadian landscape provides a robust biotech ecosystem, access to capital remains a barrier for many startups and research initiatives.
This is where international grants can make a difference. Although international grants are primarily designed to support research and development within their respective domestic regions, Canadian companies can access these opportunities through cross-border collaborations and strategic partnerships, particularly for those that address global health challenges, providing the necessary funding to accelerate innovative research.
The Future Outlook
Looking ahead, the upcoming decades promise to radically transform the neuroscientific landscape. Significant breakthroughs in the treatment of neurological disorders is expected, with precision medicine, psychedelics, and RNA technologies leading the way. Furthermore, the global market for these therapies is projected to grow exponentially, providing Canada with the opportunity to play a pivotal role.
Precision Medicine: The Dawn of Predictive Neurology
Precision medicine is expanding through the application of advanced imaging techniques and machine learning algorithms that allow for precise mapping of disease progression and treatment response in real-time. Increased integration of patient-specific data into clinical trials is also predicted as supported by improved drug efficacy. Integrating the use of deep phenotyping techniques in neuropsychiatric disorders, such as schizophrenia and major depressive disorder, allows for a better understanding of disease heterogeneity, resulting in better treatment outcomes (Fernandes et al., 2017).
In the near future, precision medicine will have evolved into predictive neurology, where the focus shifts from treatment to prevention. Advances in genomics and AI, increased multimodal data integration, and cutting-edge technologies will enable us to predict the onset of neurological conditions decades before symptoms appear, allowing for personalized interventions at earlier stages of the disease.
Canadian companies remain poised to be at the forefront of this shift by leveraging their expertise in AI and machine learning to develop predictive models that can identify at-risk individuals and tailor interventions to their specific needs. This will not only improve patient outcomes but also reduce the overall burden on the Canadian healthcare system.
Psychedelics: Mainstream Mental Health Solutions
Psychedelics are rapidly gaining attention in neuroscience due to their potential to treat a range of neuropsychiatric disorders, including depression, anxiety, post-traumatic stress disorder (PTSD), and substance use disorders. Within the next decades, psychedelics will have moved from experimental therapies to mainstream mental health treatments. Complemented with diminishing stigma surrounding the medical use of these substances, they are projected to be widely accepted as effective treatments for a range of mental health challenges.
Recent clinical trials have shown that psilocybin-assisted therapy can result in sustained reductions in depression and anxiety, with effects lasting several months after a single treatment (Griffiths et al., 2016). Alterations in brain network connectivity (Carhart-Harris et al., 2012) have been implicated with changes in self-referential processing, emotional regulation, and cognitive flexibility, which are crucial in psychiatric disorders characterized by rigid thought patterns. Additionally, psychedelics have also been shown to promote neuroplasticity by enhancing synaptogenesis and dendritic spine growth, offering potential long-term benefits following acute administration (Ly et al., 2018).
Optimization of the therapeutic protocols for psychedelic use is the way forward by exploring individual patient responses and integrating psychedelics into precision medicine frameworks. While regulatory hurdles remain, the potential of psychedelics to revolutionize mental health treatment is clear, with ongoing studies aimed at validating their efficacy and safety across diverse patient populations (Johnson & Griffiths, 2017).
As Canada continues to lead this domain with growing number of clinical trials and new treatment centers opening across the country, the economic impact of this shift will be substantial, creating new jobs and attracting significant investment in the biotech sector.
RNA Technologies: The Era of Gene Therapy
RNA technologies show significant promise towards becoming a cornerstone of neuroscience within the upcoming decades. By addressing the root genetic causes rather than just alleviating symptoms, gene therapies that not only treat but potentially cure currently incurable neurological disorders, such as Alzheimer’s, Parkinson’s, and ALS, would offer hope to millions of patients worldwide.
Genetic tools such as RNA sequencing (RNA-Seq) by offering detailed insights into the complex transcriptomic landscapes of different brain regions, holds promise in enabling the discovery of novel biomarkers and therapeutic targets (Lein et al., 2017). The integration of RNA technologies with CRISPR-based systems could further accelerate precision medicine in neuroscience, allowing for more targeted and efficient interventions. Going forward, the combination of RNA therapeutics with advanced delivery systems, such as nanoparticles or viral vectors, could overcome current challenges in delivering treatments across the blood-brain barrier, expanding the potential of RNA-based approaches to a wider range of neurological disorders (Saraiva et al., 2016). Through advancing research and clinical trials, RNA technologies are expected to become central to personalized treatments, improving patient outcomes in complex brain diseases.
Canadian firms, with their strong foundation in RNA research, will be instrumental in developing these therapies. However, the collaboration between academia, industry, and government will prove to be the pivotal factor in bringing these innovations to market and ensuring that Canada remains a leader in the field.
Finance the Future: Domestic & International Grants For Innovation
To fully realize the potential of these advancements, access to substantial funding will be a prerequisite. Through cross-border collaborations, global health initiatives and innovation grants, Canadian innovators can gain access to a wide array of domestic and international initiatives, to secure the desired funding, driving their research and developmental activities.
Internationally, the EUREKA Network, Horizon Europe, and NIH grants facilitate cutting-edge research and market-driven innovation opportunities for Canadian innovators in the neuroscientific and precision medicine domain. Furthermore, platforms such as the Canada-Israel Industrial R&D Foundation (CIIRDF) and BIRAC encourage global collaboration, fostering advancements in the healthcare sector.
Within US, innovation grants, through their unique award profile, offer specific grants designed to support early-stage, high-risk research, that address global health challenges with worldwide implications and offer significant benefit to the U.S. health landscape. Canadian startups working in the domain of neurotechnology, such as big data in healthcare, neurodata & cloud technology and those in the psychedelic research space may prove to be prime candidates for receiving such grants to fund their innovative projects that may not yet attract traditional investors.
Securing both domestic and international grants requires a strategic approach, wherein companies must clearly demonstrate the global significance of their work and the potential impact on public health. By leveraging industry expertise to develop the tailored strategic approach required to secure funding, building strong partnerships with international institutions and maximizing the innovation network facilitated by the industry experts, Canadian businesses can position themselves at the forefront of this new era in neuroscientific innovation.
Seize the Opportunity!
The convergence of precision medicine, psychedelics, and RNA technologies is poised to revolutionize neuroscience over the next two decades. The development of groundbreaking therapies presents a unique opportunity for Canadian innovators and businesses to lead this charge that promises to change the future of human health.
However, realizing this potential requires more than just cutting-edge research and scientific ingenuity. It demands strategic partnerships, a supportive regulatory environment, and access to robust funding. Grants offer a remarkable pathway to secure the financial resources needed to accelerate innovation and bring these therapies to market.
As we look to the future of neuroscience, the journey ahead promises to be challenging but rewarding, in both patient and economic outcomes. The time is now for Canadian businesses to seize the opportunity and position themselves at the forefront of this new era in neuroscience.
Let’s work together to pave the way for a healthier and innovative world! Explore our strategic financing solution and unlock the gateway to maximizing your full innovative potential.
Lein, E. S., Belgard, T. G., Hawrylycz, M., & Molnár, Z. (2017). Transcriptomic perspectives on neocortical structure, development, and evolution. Annual Review of Neuroscience, 40, 629–652. https://doi.org/10.1146/annurev-neuro-070815-013858
Rinaldi, C., & Wood, M. J. (2018). Antisense oligonucleotides: The next frontier for treatment of neurological disorders. Nature Reviews Neurology, 14(1), 9–21. https://doi.org/10.1038/nrneurol.2017.148
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016). Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. Journal of Controlled Release, 235, 34–47. https://doi.org/10.1016/j.jconrel.2016.05.044
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., … & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138-2143. https://doi.org/10.1073/pnas.1119598109
Ly, C., Greb, A. C., Cameron, L. P., Wong, R. J., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., & McKinney, R. R. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170-3182. https://doi.org/10.1016/j.celrep.2018.05.022
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197. https://doi.org/10.1177/0269881116675513
Rabinovici, G. D., Gatsonis, C., Apgar, C., Chaudhary, K., Gareen, I., Hanna, L., … & Carrillo, M. C. (2019). Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. Jama, 321(13), 1286-1294. doi:10.1001/jama.2019.2000
Fernandes, B. S., Williams, L. M., Steiner, J., Leboyer, M., Carvalho, A. F., & Berk, M. (2017). The new field of ‘precision psychiatry’. BMC medicine, 15, 1-7. https://doi.org/10.1186/s12916-017-0849-x
